GEN Exclusives

More »

GEN News Highlights

More »
Oct 1, 2008

Panacea Biotec to Invest $13.3M in PharmAthene

  • Panacea Biotec will purchase PharmAthene shares for $13.1 million, which will give it 14.5% ownership of PharmAthene.

    In a related agreement, PharmAthene has the first right of negotiation to distribute Panacea’s biodefense products in the U.S. The firm also has the right to enter into discussions with Panacea regarding potential development and manufacture of PharmAthene’s biodefense products by Panacea.

    Panacea is buying approximately 3.73 million PharmAthene shares  for $3.50 per share. This represents a 97% premium over the firm’s closing price yesterday. At close of this transaction, expected tomorrow, Panacea will receive 12-month warrants to purchase up to approximately 2.75 million additional shares of PharmAthene common stock at an exercise price of $5.10 per share.

    During the next three years Panacea Biotec agreed to not purchase additional shares of PharmAthene stock without the prior written consent of PharmAthene. Panacea Biotec's subsidiary, Kelisia Holdings through which this agreement was implemented, will be granted limited rights in future private financings by PharmAthene to maintain its current ownership level. In addition, PharmAthene will retain full rights to its proprietary information and technology and full management and operational control.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »